Company news
Contineum Therapeutics, Inc. (NASDAQ:CTNM) news
Every Contineum Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference
August 25, 2026
Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones
July 30, 2026
Contineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference
June 1, 2026
Contineum Therapeutics to Present at the 2026 RBC Capital Markets Global Healthcare Conference
May 12, 2026
Contineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International Conference
May 11, 2026
Contineum Therapeutics Reports First-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones
May 5, 2026
Contineum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 1, 2026
Contineum Therapeutics Reports Positive Topline Data From Its Exploratory PIPE-791 Phase 1b Trial in Chronic Pain
April 30, 2026
Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones
March 5, 2026
Contineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare Conference
March 3, 2026
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 28, 2026
Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering
December 11, 2025
Contineum Therapeutics Announces Proposed $75.0 Million Public Offering
December 11, 2025
Contineum Therapeutics to Attend the 8th Annual Evercore Healthcare Conference
November 24, 2025
Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Scler...
November 20, 2025
Contineum Therapeutics Reports Third-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones
October 30, 2025
Contineum Therapeutics Reports Positive Topline Data From Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791
September 18, 2025
Contineum Therapeutics to Present at September Investor Conferences
August 28, 2025
Contineum Therapeutics Reports Second-Quarter 2025 Financial Results; Updates Key Clinical Development Milestones
August 5, 2025
Contineum Therapeutics Provides Update on Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791
June 25, 2025
Contineum Therapeutics to Present at the 2025 RBC Capital Markets Global Healthcare Conference
May 15, 2025
Contineum Therapeutics Reports First-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones
May 14, 2025
Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development
April 28, 2025
Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors
March 17, 2025
Contineum Therapeutics to Present at the Stifel 2025 Virtual CNS Forum
March 12, 2025
Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones
March 6, 2025
Contineum Therapeutics Initiates Patient Dosing in Phase 1b Chronic Pain Trial of PIPE-791
March 4, 2025
Contineum Therapeutics to Present at the 2025 Leerink Partners Global Healthcare Conference
March 3, 2025
Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (...
January 8, 2025
Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791
December 16, 2024
Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference
November 25, 2024
Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application ...
November 18, 2024
Contineum Therapeutics to Attend Upcoming Investor Conferences
November 13, 2024
Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
November 6, 2024
Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences
August 28, 2024
Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 13, 2024
Contineum Therapeutics Announces Publication of Encouraging Data in the Proceedings of the National Academy of Sciences on PIPE-307, Its ...
July 31, 2024
Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors
June 24, 2024
Contineum Therapeutics to Present at the 45th Annual Goldman Sachs Healthcare Conference
June 4, 2024
Contineum Therapeutics Announces Appointment of John Healy as General Counsel & Corporate Secretary
June 3, 2024
Contineum Therapeutics Announces Appointment of Troy Ignelzi to Board of Directors
May 20, 2024
Contineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 16, 2024